Silicon Valley Embraces Unregulated Chinese Peptides Amid Safety Warnings

Gray‑market peptides imported from China have become a growing trend in parts of Silicon Valley, turning up at hacker houses, start‑up offices and themed “peptide raves” where attendees mix and inject drugs bought as “for research use only.” Peptides are short chains of amino acids used to regulate hormones and inflammation.

While GLP‑1 drugs such as semaglutide and tirzepatide are approved for weight loss, many other compounds circulating in the tech scene — including BPC‑157, TB‑500, oxytocin, epitalon, melanotan II and experimental retatrutide — are not FDA approved for human use. U.S. customs data show imports of hormone and peptide compounds from China roughly doubled to $328 million in the first three quarters of 2025, up from $164 million in the same period of 2024, reflecting rising demand for both prescription GLP‑1s and unapproved peptide formulations.

Users typically buy powdered peptides from Chinese manufacturers or U.S. intermediaries, receive vials labeled for research only, reconstitute them with sterile water and self‑inject with insulin syringes. Suppliers and enthusiasts say the off‑market products can cost a fraction of prescription alternatives, and small groups within companies often spur broader adoption.

The Food and Drug Administration has warned that many peptides pose “serious safety risks” because of contamination and immune reactions, and it has barred pharmacies from compounding them, though enforcement has been uneven.

Key Topics

Tech, Silicon Valley, China, Fda, Retatrutide